AR and triple-negative breast carcinoma: For example, preliminary results indicate that the PREDICT AR test (gene expression profiling) was significantly associated with OS in triple-negative breast cancer patients treated with enzalutamide.30 Correct patient selection will be key if AR targeted therapy is to have a future in the management of EOC.